Erlotinib resistance in lung cancer cells mediated by integrin β1/Src/Akt-driven bypass signaling

Cancer Research

Volumn 73, Issue 20, 2013, Pages 6243-6253

  Kanda, Rina ^a   Kawahara, Akihiko ^b   Watari, Kosuke ^a   Murakami, Yuichi ^a,e   Sonoda, Kahori ^a   Maeda, Masashi ^a   Fujita, Hideaki ^c   Kage, Masayoshi ^b   Uramoto, Hidetaka ^d   Costa, Carlota ^f   Kuwano, Michihiko ^a   Ono, Mayumi ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b KURUME UNIVERSITY HOSPITAL   (Japan)

^c NAGASAKI INTERNATIONAL UNIVERSITY   (Japan)

^d UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

^e ST MARY S HOSPITAL   (Japan)

^f INSTITUT UNIVERSITARI DEXEUS   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2 INTEGRIN; ALPHA5 INTEGRIN; BETA1 INTEGRIN; COMPLEMENTARY DNA; DASATINIB; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN KINASE B; PROTEIN TYROSINE KINASE; SMALL INTERFERING RNA;

ARTICLE; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER RESISTANCE; CELL ADHESION; CELL SURVIVAL; CONTROLLED STUDY; DOWN REGULATION; DRUG SENSITIVITY; EGFR GENE; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; GENE; GENE EXPRESSION REGULATION; GENE MUTATION; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; INTRACELLULAR SIGNALING; LUNG ADENOCARCINOMA; LUNG CANCER; MOLECULAR CLONING; MOLECULAR DYNAMICS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RNA INTERFERENCE;

ANTIGENS, CD29; CELL ADHESION; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; GENE KNOCKDOWN TECHNIQUES; HUMANS; LUNG NEOPLASMS; ONCOGENE PROTEIN V-AKT; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; SRC-FAMILY KINASES;

EID: 84886002801     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-12-4502     Document Type: Article

References (41)

1. Sharma SV, Bell DW, Settleman J, Haber DA Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer 2007; 7:169-81.
2. Mitsudomi T, Yatabe Y. Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer. Cancer Sci 2007; 98:1817-24.
3. Inoue A, Suzuki T, Fukuhara T., Maemondo M, Kimura Y, Morikawa N., et al Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations. J Clin Oncol 2006; 24:3340-6.
4. Zhou Q, Zhang XC, Chen Z.H., Yin XL, Yang JJ, Xu CR, et al Relative abundance of EGFR mutations predicts benefit from gefitinib treatment for advanced non-small-cell lung cancer. J Clin Oncol 2011; 29:3316-21.
5. Rosell R, Carcereny E, Gervais R., Vergnenegre A, Massuti B, Felip E., et al Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-smallcell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012; 13:239-46.
6. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S., Okimoto RA, Brannigan BW, et al Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004; 350:2129-39.
7. Garraway LA, Janne PA Circumventing cancer drug resistance in the era of personalized medicine. Cancer Discov 2012; 2:214-216.
8. Kobayashi S, Boggon TJ, Dayaram T, Jäanne PA, Kocher O., Meyerson M, et al EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 2005; 352:786-92.
9. Pao W, Miller VA, Politi K.A., Riely GJ, Somwar R, Zakowski MF, et al Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2005; 2:e73.
10. Engelman JA, Zejnullahu K, Mitsudomi T., Song Y, Hyland C, Park J.O., et al MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007; 316:1039-43.
11. Ellis LM, Hicklin DJ Resistance to targeted therapies: refining anticancer therapy in the era of molecular oncology. Clin Cancer Res 2009; 15:7471-78.
12. Huang S, Hoölzel M, Knijnenburg T., Schlicker A, Roepman P, McDermott U., et al MED12 controls the response to multiple cancer drugs through regulation of TGF-β receptor signaling. Cell 2012; 151:937-50.
13. Ono M, Kuwano M. Molecular mechanisms of epidermal growth factor receptor (EGFR) activation and response to gefitinib and other EGFRtargeting drugs. Clin Cancer Res 2006; 12:7242-51.
14. Yamamoto C, Basaki Y, Kawahara A., Nakashima K, Kage M, Izumi H., et al Loss of PTEN expression by blocking nuclear translocation of EGR1 in gefitinib-resistant lung cancer cells harboring epidermal growth factor receptor-activating mutations. Cancer Res 2010; 70: 8715-25.
15. Garofalo M, Romano G, Di Leva G, Nuovo G, Jeon Y.J., Ngankeu A., et al EGFR and MET receptor tyrosine kinase-altered microRNA expression induces tumorigenesis and gefitinib resistance in lung cancers. Nat Med 2011; 18:74-82.
16. Okamoto K, Okamoto I, Hatashita E., Kuwata K, Yamaguchi H, Kita A., et al Overcoming erlotinib resistance in EGFR mutation-positive non-small cell lung cancer cells by targeting survivin. Mol Cancer Ther 2012; 11:204-13.
17. Tabara K, Kanda R, Sonoda K., Kubo T, Murakami Y, Kawahara A., et al Loss of activating EGFR mutation gene contributes to acquired resistance to EGFR tyrosine kinase inhibitors in lung cancer cells. PLoS ONE 2012; 7:e41017
18. Ono M, Hirata A, Kometani T., Miyagawa M, Ueda S, Kinoshita H., et al Sensitivity to gefitinib (Iressa, ZD1839) in non-small cell lung cancer cell lines correlates with dependence on the epidermal growth factor (EGF) receptor/extracellular signal-regulated kinase 1/2 and EGF receptor/ Akt pathway for proliferation. Mol Cancer Ther 2004; 3:465-72.
19. Koike K, Kawabe T, Tanaka T., Toh S, Uchiumi T, Wada M., et al A canalicular multispecific organic anion transporter (cMOAT) antisense cDNA enhances drug sensitivity in human hepatic cancer cells. Cancer Res 1997; 57:5475-9.
20. Xu H, Zeng L, Peng H., Chen S, Jones J, Chew T.L., et al HMG-CoA reductase inhibitor simvastatin mitigates VEGF-induced "inside-out" signaling to extracellular matrix by preventing RhoA activation. Am J Physiol Renal Physiol 2006; 291:F995-1004.
21. Uramoto H, Shimokawa H, Hanagiri T., Kuwano M, Ono M. Expression of selected gene for acquired drug resistance to EGFR-TKI in lung adenocarcinoma. Lung Cancer 2011; 73:361-5.
22. Onitsuka T, Uramoto H, Nose N., Takenoyama M, Hanagiri T, Sugio K., et al Acquired resistance to gefitinib: the contribution of mechanisms other than the T790M, MET, and HGF status. Lung Cancer 2010; 68:198-203.
23. Kawahara A, Yamamoto C, Nakashima K., Azuma K, Hattori S, Kashihara M., et al Molecular diagnosis of activating EGFR mutations in nonsmall cell lung cancer using mutation-specific antibodies for immunohistochemical analysis. Clin Cancer Res 2010; 16:3163-70.
24. Barczyk M, Carracedo S, Gullberg D. Intgrins. Cell Tissue Res 2010; 339:269-80.
25. Ye F, Kim C, Ginsberg H. Reconstitution of integrin activation. Blood 2012; 119:26-33.
26. Thomas SM, Brugge JS Cellular functions regulated by Src family kinases. Annu Rev Cell Dev Biol 1997; 13:513-609.
27. Ju L, Zhou C, Li W., Yan L. Integrin beta1 over-expression associates with resistance to tyrosine kinase inhibitor gefitinib in non-small cell lung cancer. J Cell Biochem 2010; 111:1565-74.
28. Rintoul RC, Sethi T. Extracellular matrix regulation of drug resistance in small-cell lung cancer. Int J Radiat Biol 2007; 83:733-41.
29. Giannelli G, Azzariti A, Fransvea E., Porcelli L, Antonaci S, Paradiso A. Laminin-5 offsets the efficacy of gefitinib ('Iressa') in hepatocellular carcinoma cells. Br J Cancer 2004; 91:1964-9.
30. Helleman J, Jansen MP, Burger C, van der Burg ME, Berns EM. Integrated genomics of chemotherapy resistant ovarian cancer: a role for extracellular matrix, TGFbeta and regulating microRNAs. Int J Biochem Cell Biol 2010; 42:25-30.
31. Eke I, Deuse Y, Hehlgans S., Gurtner K, Krause M, Baumann M., et al β1 integrin/FAK/cortactin signaling is essential for human head and neck cancer resistance to radiotherapy. J Clin Invest 2012; 122:1529-40.
32. Natali PG, Nicotra MR, Bartolazzi A, Cavaliere R., Bigotti A. Integrin expression in cutaneous malignant melanoma: association of the alpha 3/beta 1 heterodimer with tumor progression. Int J Cancer 1993; 54:68-72.
33. Zutter MM, Santoro SA, Staatz W.D., Tsung YL Re-expression of the alpha 2 beta 1 integrin abrogates the malignant phenotype of breast carcinoma cells. Proc Natl Acad Sci U S A 1995; 92:7411-5.
34. Mitra AK, Sawada K, Tiwari P., Mui K, Gwin K, Lengyel E. Ligandindependent activation of c-Met by fibronectin and α5β1- integrin regulates ovarian cancer invasion and metastasis. Oncogene 2011; 30: 1566-76.
35. Yamaguchi T, Yanagisawa K, Sugiyama R., Hosono Y, Shimada Y, Arima C., et al NKX2-1/TITF1/TTF1-induced ROR1 is required to sustain EGFR signaling in lung adenocarcinoma. Cancer Cell 2012; 21:348-61.
36. Song L, Morris M, Bagui T., Lee FY, Jove R, Haura EB Dasatinib (BMS354825) selectively induces apoptosis in lung cancer cells dependent on epidermal growth factor receptor signaling for survival. Cancer Res 2010; 66:5542-8.
37. Yoshida T, Okamoto I, Okamoto W., Hatashita E, Yamada Y, Kuwata K., et al Effects of Src inhibitors on cell growth and epidermal growth factor receptor and MET signaling in gefitinib-resistant non-small cell lung cancer cells with acquired MET amplification. Cancer Sci 2010; 101:167-72.
38. Rexer BN, Ham AJ, Rinehart C, Hill S., Granja-Ingram N de M, Gonzalez Angulo AM, et al. Phosphoproteomic mass spectrometry profiling links Src family kinases to escape from HER2 tyrosine kinase inhibition. Oncogene 2011; 30:4163-74.
39. Haura EB, Tanvetyanon T, Chiappori A., Williams C, Simon G, Antonia S., et al Phase I/II study of the Src inhibitor dasatinib in combination with erlotinib in advanced non-small-cell lung cancer. J Clin Oncol 2010; 28:1387-94.
40. Millard M, Odds S, Neamati N. Integrin targeted therapeutics. Theranostics 2011; 1:154-88
41. Besse B, Tsao LC, Chao D.T., Fang Y., Soria JC, Almokadem S, et al Phase Ib safety and pharmacokinetic study of volociximab, an antiα5β1 integrin antibody, in combination with carboplatin and paclitaxel in advanced non-small-cell lung cancer. Ann Oncol 2013; 24:90-6.